A review of picotamide in the reduction of cardiovascular events in diabetic patients

Figures & data

Table 1 Baseline characteristics and side-effects of both ADEP and DAVID trials

	ADEP study		DAVID study
	Picotamide	Placebo	Picotamide	Aspirin
Dosage	300 mg bid		600 mg bid	320 mg od
Clinical characteristics
	n = 1150	n = 1154	n = 603	n = 606
Age	63.4 + 7.3	62.9 + 7.4	63.8 + 7.2	64.6 + 7.3
Diabetes	20%	18%	100%	100%
PAD	100%	100%	100%	100%
Smoke	39.6%	37.1%	30.5%	28.4%
Hypertension	34.5%	37.5%	58.2%	55.6%
Dyslipidemia	36.5%	35.8%	38%	38.4%
Previous stroke	1.4%	1.7%	10.4%	10.2%
Coronary heart disease	15%	12.7%	19.4%	19%
Side-effects
Gastro-intestinal	11.1%	12%	10.9%	18.3%
Total	14.3%	13.5%	25.6%	33.9%

Abbreviations: bid, twice a day; od, once a day; PAD, peripheral artery disease.

Table 2 Duration of follow-up, endpoints and statistically relevant results of both ADEP and DAVID trials

	ADEP study		DAVID study
Follow-up	18 months		24 months
Primary endpoints	Major events: death, MI, stroke, amputation		Overall mortality
Secondary endpoints	Minor events: UA, TIA, hypertension, renal failure, deterioration of PAD		Stroke, MI, amputation, other death
Statistical significance	Major plus minor events (“on treatment analysis”)		Overall mortality
Percentage of event in statistically relevant endpoints	picotamide	placebo	picotamide	aspirin
	10.1%	13%	3%	5.5%

Abbreviations: MI, myocardial infarction; PAD, peripheral artery disease;TIA, transient ischemic attack; UA, unstable angina.